These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 15255179)

  • 1. Searching for the most effective screening system to identify cell-active inhibitors of beta-secretase.
    Middendorp O; Lüthi U; Hausch F; Barberis A
    Biol Chem; 2004 Jun; 385(6):481-5. PubMed ID: 15255179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. beta-Secretase, APP and Abeta in Alzheimer's disease.
    Vassar R
    Subcell Biochem; 2005; 38():79-103. PubMed ID: 15709474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo beta-secretase 1 inhibition leads to brain Abeta lowering and increased alpha-secretase processing of amyloid precursor protein without effect on neuregulin-1.
    Sankaranarayanan S; Price EA; Wu G; Crouthamel MC; Shi XP; Tugusheva K; Tyler KX; Kahana J; Ellis J; Jin L; Steele T; Stachel S; Coburn C; Simon AJ
    J Pharmacol Exp Ther; 2008 Mar; 324(3):957-69. PubMed ID: 18156464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent advances in the development of gamma-secretase inhibitors.
    Josien H
    Curr Opin Drug Discov Devel; 2002 Jul; 5(4):513-25. PubMed ID: 12197309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. gamma-Secretase as a target for drug intervention in Alzheimer's disease.
    Harrison T; Churcher I; Beher D
    Curr Opin Drug Discov Devel; 2004 Sep; 7(5):709-19. PubMed ID: 15503873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Secretase inhibitors for Alzheimer's disease: challenges of a promiscuous protease.
    Pollack SJ; Lewis H
    Curr Opin Investig Drugs; 2005 Jan; 6(1):35-47. PubMed ID: 15675602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reductions in beta-amyloid concentrations in vivo by the gamma-secretase inhibitors BMS-289948 and BMS-299897.
    Anderson JJ; Holtz G; Baskin PP; Turner M; Rowe B; Wang B; Kounnas MZ; Lamb BT; Barten D; Felsenstein K; McDonald I; Srinivasan K; Munoz B; Wagner SL
    Biochem Pharmacol; 2005 Feb; 69(4):689-98. PubMed ID: 15670587
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential effects of gamma-secretase and BACE1 inhibition on brain Abeta levels in vitro and in vivo.
    Elvang AB; Volbracht C; Pedersen LØ; Jensen KG; Karlsson JJ; Larsen SA; Mørk A; Stensbøl TB; Bastlund JF
    J Neurochem; 2009 Sep; 110(5):1377-87. PubMed ID: 19519664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 2,3-Benzodiazepin-1,4-diones as peptidomimetic inhibitors of gamma-secretase.
    Prasad CV; Vig S; Smith DW; Gao Q; Polson CT; Corsa JA; Guss VL; Loo A; Barten DM; Zheng M; Felsenstein KM; Roberts SB
    Bioorg Med Chem Lett; 2004 Jul; 14(13):3535-8. PubMed ID: 15177468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Boom in the development of non-peptidic beta-secretase (BACE1) inhibitors for the treatment of Alzheimer's disease.
    Silvestri R
    Med Res Rev; 2009 Mar; 29(2):295-338. PubMed ID: 18651582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular-modeling based design, synthesis, and activity of substituted piperidines as gamma-secretase inhibitors.
    Gundersen E; Fan K; Haas K; Huryn D; Steven Jacobsen J; Kreft A; Martone R; Mayer S; Sonnenberg-Reines J; Sun SC; Zhou H
    Bioorg Med Chem Lett; 2005 Apr; 15(7):1891-4. PubMed ID: 15780628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dynamics of {beta}-amyloid reductions in brain, cerebrospinal fluid, and plasma of {beta}-amyloid precursor protein transgenic mice treated with a {gamma}-secretase inhibitor.
    Barten DM; Guss VL; Corsa JA; Loo A; Hansel SB; Zheng M; Munoz B; Srinivasan K; Wang B; Robertson BJ; Polson CT; Wang J; Roberts SB; Hendrick JP; Anderson JJ; Loy JK; Denton R; Verdoorn TA; Smith DW; Felsenstein KM
    J Pharmacol Exp Ther; 2005 Feb; 312(2):635-43. PubMed ID: 15452193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and synthesis of highly active Alzheimer's beta-secretase (BACE1) inhibitors, KMI-420 and KMI-429, with enhanced chemical stability.
    Kimura T; Shuto D; Hamada Y; Igawa N; Kasai S; Liu P; Hidaka K; Hamada T; Hayashi Y; Kiso Y
    Bioorg Med Chem Lett; 2005 Jan; 15(1):211-5. PubMed ID: 15582441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The proteins BACE1 and BACE2 and beta-secretase activity in normal and Alzheimer's disease brain.
    Stockley JH; O'Neill C
    Biochem Soc Trans; 2007 Jun; 35(Pt 3):574-6. PubMed ID: 17511655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fragment-based discovery of BACE1 inhibitors using functional assays.
    Godemann R; Madden J; Krämer J; Smith M; Fritz U; Hesterkamp T; Barker J; Höppner S; Hallett D; Cesura A; Ebneth A; Kemp J
    Biochemistry; 2009 Nov; 48(45):10743-51. PubMed ID: 19799414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 3-Substituted gem-cyclohexane sulfone based gamma-secretase inhibitors for Alzheimer's disease: conformational analysis and biological activity.
    Jelley RA; Elliott J; Gibson KR; Harrison T; Beher D; Clarke EE; Lewis HD; Shearman M; Wrigley JD
    Bioorg Med Chem Lett; 2006 Jul; 16(14):3839-42. PubMed ID: 16682202
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KMI-358 and KMI-370, highly potent and small-sized BACE1 inhibitors containing phenylnorstatine.
    Kimura T; Shuto D; Kasai S; Liu P; Hidaka K; Hamada T; Hayashi Y; Hattori C; Asai M; Kitazume S; Saido TC; Ishiura S; Kiso Y
    Bioorg Med Chem Lett; 2004 Mar; 14(6):1527-31. PubMed ID: 15006396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and evaluation of succinoyl-caprolactam gamma-secretase inhibitors.
    Thompson LA; Liauw AY; Ramanjulu MM; Kasireddy-Polam P; Mercer SE; Maduskuie TP; Glicksman M; Roach AH; Meredith JE; Liu RQ; Combs AP; Higaki JN; Cordell B; Seiffert D; Zaczek RC; Robertson DW; Olson RE
    Bioorg Med Chem Lett; 2006 May; 16(9):2357-63. PubMed ID: 16473009
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Computational approaches to the prediction of blood-brain barrier permeability: A comparative analysis of central nervous system drugs versus secretase inhibitors for Alzheimer's disease.
    Rishton GM; LaBonte K; Williams AJ; Kassam K; Kolovanov E
    Curr Opin Drug Discov Devel; 2006 May; 9(3):303-13. PubMed ID: 16729726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hydroxytriamides as potent gamma-secretase inhibitors.
    Prasad CV; Wallace OB; Noonan JW; Sloan CP; Lau W; Vig S; Parker MF; Smith DW; Hansel SB; Polson CT; Barten DM; Felsenstein KM; Roberts SB
    Bioorg Med Chem Lett; 2004 Apr; 14(8):1917-21. PubMed ID: 15050627
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.